Ann Hematol

1. STASIK S, Eckardt JN, Rollig C, Baldus CD, et al
   PRDM16 expression is an independent prognostic factor in AML with the double-mutant NPM1/FLT3-ITD genotype.
   Ann Hematol. 2026;105:49.
   

   >> Share

   
   
2. PEREZ-LAMAS L, Manzanares M, Hernandez Boluda JC, Casado Montero LF, et al
   One-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with Imatinib.
   Ann Hematol. 2026;105:40.
   

   >> Share

   
   
3. JIANG R, Zhang Z, Liu Y, Qu W, et al
   KIT Mutant/Core binding factor-negative acute myeloid leukemia might be a complex subgroup with dismal prognosis: a single-center retrospective analysis.
   Ann Hematol. 2026;105:42.
   

   >> Share

   
   
4. WANG X, Mo W, Chen M, Sui J, et al
   Vascular complications in NPM1-Mutated acute myeloid leukemia: clinical features and prognosis.
   Ann Hematol. 2026;105:41.
   

   >> Share

   
   
5. ROBERT F, Badja C, Boushaki S, Degasperi A, et al
   BCOR mutations define a therapeutic vulnerability to DHODH Inhibition in acute myeloid leukemia.
   Ann Hematol. 2026;105:32.
   

   >> Share

   
   
6. AL-SHIBLY R, Qassim N, Alfarsi K, AlShemmari S, et al
   Contraceptives in chronic lymphocytic leukemia (CLL): a narrative review.
   Ann Hematol. 2026;105:30.
   

   >> Share

   
   

   
   Biochem Biophys Res Commun

7. ZHANG W, Liu Y, Xiao X, Zheng Q, et al
   Multi-scale transcriptomics analysis reveals MHC suppression in MEF2D fusion positive B-cell acute lymphoblastic leukemia.
   Biochem Biophys Res Commun. 2026;800:153274.
   

   >> Share

   
   

   
   Blood

8. LEYTE-VIDAL A, Shah NP
   How I individualize frontline treatment for chronic-phase CML.
   Blood. 2026;147:329-336.
   

   >> Share

   
   
9. CHALANDON Y, Simonetta F, Masouridi-Levrat S
   How I approach hematopoietic stem cell transplantation for CML in a TKI world.
   Blood. 2025 May 12:blood.2024026512. doi: 10.1182/blood.2024026512.
   

   >> Share

   
   
10. SOVERINI S, Castagnetti F
    How I evaluate and treat resistance and relapse in CML.
    Blood. 2026;147:337-346.
    

    >> Share

    
    
11. MAURO MJ
    How I treat advanced phases of CML.
    Blood. 2026;147:369-378.
    

    >> Share

    
    
12. GOTLIB J
    Introduction to a How I Treat series on chronic myeloid leukemia.
    Blood. 2026;147:319-320.
    

    >> Share

    
    

    
    Bone Marrow Transplant

13. SALHOTRA A, Yang D, Al Malki MM, Mokhtari S, et al
    Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis.
    Bone Marrow Transplant. 2026;61:82-91.
    

    >> Share

    
    

    
    Br J Haematol

14. SHANMUGANATHAN N, Grigg A
    A critical review of management of allogeneic transplant-eligible adults with Ph+ acute lymphoblastic leukaemia.
    Br J Haematol. 2026;208:39-53.
    

    >> Share

    
    
15. HERMANS SJF, Versluis J, van Werkhoven ED, van Norden Y, et al
    Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients.
    Br J Haematol. 2026;208:179-188.
    

    >> Share

    
    
16. WU LX, Liao MY, Zhao MY, Yan N, et al
    Prognostic value of CEBPA bZIP signatures in cytogenetically normal acute myeloid leukaemia.
    Br J Haematol. 2026;208:170-178.
    

    >> Share

    
    
17. ZHANG X, Wang L, Kuang N, Yang J, et al
    Immune reconstitution after CD7 CAR-T cell therapy for refractory/relapsed acute T-lymphoblastic leukaemia/lymphoblastic lymphoma (R/R T-ALL/LBL).
    Br J Haematol. 2025 Oct 19. doi: 10.1111/bjh.70201.
    

    >> Share

    
    
18. DUPONT M, Derouault P, Pascal V, Dmytruk N, et al
    CLL-like stereotyped BCRs are equally produced in young and old healthy adults, share features of public clonotypes and may be stuck at a pre-germinal centre stage.
    Br J Haematol. 2026;208:106-115.
    

    >> Share

    
    
19. SHICHIJO T, Tatetsu H, Higuchi Y, Miyakawa T, et al
    Prognostic impact of valemetostat in relapsed/refractory adult T-cell leukaemia-lymphoma.
    Br J Haematol. 2025 Oct 23. doi: 10.1111/bjh.70219.
    

    >> Share

    
    
20. XU Q, Wang L, Hu S, Liao N, et al
    Risk factors for DIC in paediatric APL: Insights from the CCLG-APL 2016 study.
    Br J Haematol. 2026;208:200-209.
    

    >> Share

    
    
21. TAN Y, Zhao X, Suo X, Bai G, et al
    Venetoclax combined with homoharringtonine, cytarabine and aclacinomycin as induction therapy in newly diagnosed Chinese acute myeloid leukaemia patients: A multicentre phase II study.
    Br J Haematol. 2026;208:189-199.
    

    >> Share

    
    

    
    Cancer

22. BUCHRITS S, Rozental A, Korngold N, Algor O, et al
    Glucose-6-phosphate dehydrogenase deficiency is associated with improved survival in patients with acute myeloid leukemia treated with venetoclax and azacitidine.
    Cancer. 2026;132:e70265.
    

    >> Share

    
    
23. IURLO A, Cattaneo D, Fava C, Castagnetti F, et al
    Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter study.
    Cancer. 2026;132:e70261.
    

    >> Share

    
    

    
    Cancer Chemother Pharmacol

24. YANAGIMACHI M, Iwano R, Keino D, Kimizuka Y, et al
    Post-transplantation gilteritinib maintenance therapy and therapeutic drug monitoring in pediatric acute myeloid leukemia with FLT3-internal tandem duplication.
    Cancer Chemother Pharmacol. 2026;96:10.
    

    >> Share

    
    

    
    Eur J Haematol

25. MAHESWARAN S, Gordon CD, Chen EC, Patel SA, et al
    Challenges and Solutions to Implementation of Chimeric Antigen Receptor Therapies in Acute Myeloid Leukemia.
    Eur J Haematol. 2026 Jan 23. doi: 10.1111/ejh.70120.
    

    >> Share

    
    

    
    Exp Hematol

26. DUGUID A, Malouf C, Nitsche L, Halsey C, et al
    Mixed-lineage leukemia cells undergo unique adaptations in the CNS niche.
    Exp Hematol. 2026;154:105347.
    

    >> Share

    
    
27. IAQUINTA G, Lagana A, Tamburini A, Tatarelli C, et al
    Germline heterozygous SH2B3 p.Glu78Lys variant: a three-patient case series with myeloproliferative neoplasms.
    Exp Hematol. 2026;154:105333.
    

    >> Share

    
    

    
    Int J Hematol

28. NISHIWAKI S, Sugiura I, Fujisawa S, Hatta Y, et al
    Dasatinib is superior to imatinib in adult Ph + ALL: a propensity score-matched analysis of pooled JALSG trial data.
    Int J Hematol. 2026;123:24-31.
    

    >> Share

    
    
29. MAKIYAMA J, Ohno N, Jimbo K, Kawamata T, et al
    Outcomes of patients aged 70 years or younger with aggressive ATL at core hospitals for ATL treatment in Tokyo.
    Int J Hematol. 2026;123:52-62.
    

    >> Share

    
    

    
    J Clin Oncol

30. BRAUNSTEIN MJ, Williams ME
    Bridging the Gap: Pirtobrutinib for Treatment-Naive Chronic Lymphatic Leukemia.
    J Clin Oncol. 2026 Jan 20:JCO2502879. doi: 10.1200/JCO-25-02879.
    

    >> Share

    
    

    
    Leuk Lymphoma

31. CHUMNUMSIRIWATH P, Kongtim P, Lipan L, Jercan CG, et al
    Efficacy of CD19 CAR T-cell therapy for patients with B-cell acute lymphoblastic leukemia relapsed after allogeneic transplantation.
    Leuk Lymphoma. 2026 Jan 22:1-4. doi: 10.1080/10428194.2026.2619496.
    

    >> Share

    
    
32. JEFFREY A, Mason G, Coyle L, Mackinlay N, et al
    The spectrum of tonsillar involvement in chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2026 Jan 19:1-9. doi: 10.1080/10428194.2026.2616323.
    

    >> Share

    
    

    
    Leuk Res

33. LOK V, Moffitt K, Sastow D, Medawar G, et al
    Clinical utility of interim bone marrow biopsies in FLT3 mutant acute myeloid leukemia.
    Leuk Res. 2025;161:108147.
    

    >> Share

    
    
34. SAMMUT R, Benichou A, Wang C, Loschi M, et al
    Impact of autoimmune diseases or inflammatory manifestations on response and outcome in high-risk myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Leuk Res. 2026;161:108168.
    

    >> Share

    
    

    
    Leukemia

35. OEHLER VG, Sala-Torra O, Gilderman N, Beppu L, et al
    Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology.
    Leukemia. 2026 Jan 23. doi: 10.1038/s41375-025-02852.
    

    >> Share

    
    
36. WANG Y, Wang X, Li M, Song H, et al
    Distal enhancer RNAs regulate alternative promoter usage of MYB and drug resistance in human leukemia cells.
    Leukemia. 2026 Jan 22. doi: 10.1038/s41375-026-02862.
    

    >> Share

    
    
37. ANSUINELLI M, Peragine N, De Propris MS, Puzzolo MC, et al
    Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia.
    Leukemia. 2026 Jan 22. doi: 10.1038/s41375-025-02855.
    

    >> Share

    
    
38. REA D, Kyrcz-Krzemien S, Sportoletti P, Mayer J, et al
    Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.
    Leukemia. 2026 Jan 19. doi: 10.1038/s41375-025-02847.
    

    >> Share

    
    

    
    PLoS One

39. FLORES-MEJIA LA, Siliceo P, Figueroa UJ, De la Cruz AA, et al
    Prediction of myeloid malignant cells in Fanconi anemia using machine learning.
    PLoS One. 2026;21:e0340578.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share